Dogwood Therapeutics announces press release availability

PUBT · 1d ago
Dogwood Therapeutics announces press release availability
  • Dogwood Therapeutics enrolled the first 200 patients in its Halneuron Phase 2b HAL-CINP trial for chemotherapy-induced neuropathic pain.
  • Top-line results from the four-week study remain targeted for fall 2026.
  • An independent unblinded statistical review in December flagged separation from placebo on pain improvement; dropout rate reported at 4.5%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200830PRIMZONEFULLFEED9764133) on July 20, 2026, and is solely responsible for the information contained therein.